



1789 TT

ScinoPharm Management Presentation

Daiwa Investment Conference New York & San Francisco 2017

May 30, 2017



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Content

- **Overview of ScinoPharm**
- **ScinoPharm's Strategies and Opportunities**
- **Operating Results & Business Updates**


Overview of ScinoPharm

ScinoPharm at a Glance

- Company specializes in high potency (steroid/cytotoxic) APIs and is expanding into sterile/aseptic injectable formulations
- Facility & organization established in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai
- 72 generic APIs in current portfolio with 25 APIs launched; 53 US DMFs filed (759 DMFs WW), 32 US DMFs in oncology APIs. 100+ NCE CRAM projects, with 5 APIs launched and 5 in phase III for NDA filing in 1-3 years
- Fully compliant with world-class cGMPs and international regulatory requirements; Certified by US FDA, EMA, EDQM, Australian TGA, Japanese PMDA



Specialty Pharmaceutical Company with Two Businesses



World Class Facilities

Taiwan

- 6.6 hectares of land, 330K sq.ft. facilities with >200M³ reactor volume
- 5 of 16 production lines equipped with high potency capabilities for cytotoxic/steroids
- Passed US FDA, EMA, EDQM, Australian TGA, Japanese PMDA inspections, & 300+ cGMP customer audits
- Provides comprehensive contract research & manufacturing services for brand drug companies
- In-house injectable plant with vial and cartridge production lines for oncologicals and peptides




China

- 6.7 hectares of land with > 250M³ reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency API
- Full scope capabilities in the development and production of APIs on small to large scales for generic & CRAM markets
- Partnerships with downstream formulation and target for global market including China





Strong Generics Product Portfolio



Note: Other (Women's Health, Gastrointestinal, Immunology and Metabolic)




ScinoPharm - Oncology API Leader




2017 Q1 Sales Distribution


By Business



By Region



By Indication





ScinoPharm's Strategies and Opportunities

Business Growth Drivers

1. Deploying the network of development, production and distribution of injectables

- Build partnerships to speed up the momentum of vertical integration
- Achieve critical mass workforce for in-house injectable plant facility

2. CRAM has promising development potential in the next three years

- Focus on small-molecule targeted therapies and CNS agents based on new mode of action
- Provide integrated service from API to formulation for niche injectables

3. Active development of Chinese and Japanese market


- Target projects to utilize capacity and accelerate growth for Changshu site
- Develop partnership with major Japanese pharmaceutical companies and international pharmaceutical groups with Japan-based operation site

4. Continue optimizing existing generic APIs

- Maintain the market share and profit of the top 5 marketed products

We are Transforming our Company

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits



Keys to Generic Formulation Business

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

Opportunity	Strategy	Tactics
✓ Already the leader in providing oncology APIs to regulated markets worldwide ✓ Injectable CMOs are in short supply ✓ Can be customer's injectables provider by developing formulations using our own oncology APIs or others' APIs, up to and including ANDA filing with FDA	✓ Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain ✓ Targeted delivery & extended release of proven APIs via 505(b)(2) fast track ✓ Collaborating with start-ups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia	✓ Expanding formulation portfolio ✓ Establishing on-site oncology injectable facility and providing an integrated supply chain ✓ Promoting our formulations via strategic alliances, especially in China and US/EU

Results

- 2 US ANDAs
- 16 co-development and cost/profit sharing products with various partners

Strategic Alliance Highlights

* Already launched


- 01 Injectable
- 02 CRAM
- 03 Market Expansion
- 04 Maintain TOP5 Profits

Partner	Product	Indications	Region	Launch Year(E)	Remarks
Genovate	Entecavir	Hepatitis B Virus	Taiwan	2013*	1 st co-developed formulation product launch
Sagent	Oncology Injectable	Myeloid Leukemia	US	2017	1 st US ANDA filing, triggering US FDA inspection in Changshu, China site
Foresee	Leuprolide	Prostate cancer	US	2019	505(b)(2) NDA CRAM + Equity
Coland	Bortezomib	Multiple Myeloma	China	2020	1 st co-developed drug in China to trigger CFDA inspection in Changshu site
	Azacitidine	MDS	China	2021	Co-developed formulation in China
Lee's Pharma	Fondaparinux	Anti-thrombotic	China	2021	Co-development collaboration
	Travoprost & Bimatoprost	Glaucoma	China	2021	
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2020	Co-developed formulation in China
US partner	Project A	Non-small cell lung cancer	US	2017	US NDA 505(b)(2). The estimated launch year is subject to US FDA review
US & China partners	Project B	Imaging agent	US	2021	ANDA with Paragraph IV filing. The estimated launch year is subject to litigation results
Baxter	5 niche injectables	Anti-cancer & antinauseant	US/EU	2020& continuing thereafter	Baxter has the right to add up to 15 additional injectable products for collaboration
Indian Int'l partner	Niche injectable	Anti-thrombotic	US/EU	2018	1st self-developed US ANDA launched. Executive right for marketing & sales

In-House Injectable Plant Progress


01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

- Taiwan-based facility will accommodate R&D, Quality Control, washing, sterilization, manufacturing, filling, lyophilization, packaging, and storage.
- Planned kick-off registration batch production by 2017. Expected submission of 1st in-house ANDA in 2018 and subsequent US FDA inspection approval in 2019
- Target products with high entry barrier or unit-pricing as in peptides and oncology agents.
- Offering CMO services for both brand and proprietary drugs



Aseptic Fill & Finish Service

- 01 **Injectable**
- 02 CRAM
- 03 Market Expansion
- 04 Maintain TOP5 Profits



CRO Phase III Product Portfolio

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

Code	Est. NDA Filing Year	Indication	Region	Regional Sales**	Remarks
A	2016*	Infectious Disease	US / EU / Asia	\$1.4 bn	Completed process validation. Anticipated launch in 2017 with demand in tons. Expected revenue of several million USD per year
B	2018	Type I,II Diabetes	US/ EU	\$2.4 bn	Intermediate project made in Changshu site. Expected revenue of several million USD per year after launch
C	2018	Advanced Hepatocellular Carcinoma, Myelofibrosis, Autoimmune disease, etc.	CN	N/A	API project made in Changshu site. CFDA granted accelerated review under its category 1.1 innovative drug. Anticipated launch in 2019 with demand in tons
D	2018	Prostate Cancer	US / EU	\$2.4 bn	Started process validation. Anticipated launch in 2019 and revenue of several million USD per year
E	2018	Parkinson's Disease	US	\$1.0 bn	Novel mechanism with promising demand. Anticipated launch in 2019 with demand in tons. Expected revenue of several million USD per year

* Already Filed ** Source: BioMedTracker, GlobalData and DataMonitor



China and Japan Market Development

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

China

- Accelerate progress to create positive cash flow
- Focus on mid- to late-phase CRO projects. Current portfolio includes agents for oncology, anti-hypertension, and diabetes
- Seek generic APIs/intermediates with large demand to increase production utilization
- Develop partnerships with downstream formulation for collaborative development and registration, realizing shared profit creation

Japan

- Among 20 customers, 6 are top 10 drug firms. Less established players have exited the more concentrated market
- Encourage local generic customers to engage more in direct business
- Support Japanese companies and foreign pharmaceutical companies to enable and extend business outreach
- With the resources in Taiwan and Changshu, API supply is more flexible and can be incorporated to injectable drug product via integrated services



Capturing Chinese Growth on Multiple Fronts

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

- MNCs and emerging virtual-model players create a sizable demand in high-quality and compliant API contract manufacturing in China
- Existing review and approval mechanisms significantly raise the entry barrier and cost structure in the Chinese drug market, requiring dedication to quality and innovation
- We have domestic presence plus world-class strength in:
 - * Global, first-tier customer base
 - * High-technical-barrier oncology APIs
 - * Quality and EHS/GMP compliance



Selected List of CRAM Projects at Changshu

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

Customer	Project Type	Product Indication/stage	Product Type	Remarks/ Market
Top 10 global pharma	CMO	Approved antidepressant drug in US	GMP Intermediate	Passed Mexican authority (APIF) GMP inspection
Top 5 global pharma	CMO	Approved African sleeping disease drug	API	Site transfer from Taiwan
Lee's Pharma	CRO / CMO	>15 projects, including brain tumor, antibiotic, hypertension, eye drops, etc.	API	China
China pharm company	CRO	Phase II/ III clinical trial for cancer	API	China
China pharm company	CRO	Phase IIb for age-related macular degeneration	API	US/China
Taigen Biotech	CRO	Phase II clinical trial for myocardial infarction	API	China/Taiwan
US-based new drug company	CRO	Phase II clinical trial for prevention of HIV infection	API	US
Aslan Pharmaceuticals	CRO	Phase II clinical trial for cancer	API	China/Global
Top 5 global pharma	CRO	Phase III clinical trial for diabetes	Intermediate	US
Top 5 global pharma	CRO	Phase I clinical trial	API	NA
US NASDAQ listed pharma	CRO	Phase III clinical trial for opioid-induced constipation	Crude API	US
US-based new drug company	CRO	Phase I clinical trial for sickle cell disease	API	US

Maintain Market Share of Existing APIs

- 2016 Major Products account for 65% of total sales

01	Injectable
02	CRAM
03	Market Expansion
04	Maintain TOP5 Profits

API Product	Indication	2016 MKT share*	# of US DMF/EDMF & other filings
Irinotecan HCl	Antineoplastic	42%	63
Paclitaxel	Antineoplastic	34%	57
Gemcitabine	Antineoplastic	24%	76
Exemestane	Antineoplastic	22%	44
Galantamine HBr	Antipsychotic	17%	38
Docetaxel Anhydrous	Antineoplastic	15%	69

*Source: IMS data from Newport





Operating Results & Business Updates

Quarterly P&L - Consolidated

In NT\$ million, except for EPS	Q1, 2017 (Reviewed)	Q1, 2016 (Reviewed)	YoY
Operating Revenue	919	1,022	-10%
Gross Profit	470	431	9%
<i>Gross margin</i>	<i>51%</i>	<i>42%</i>	
Operating Expenses	(249)	(236)	6%
Operating Income	221	195	13%
<i>Operating margin</i>	<i>24%</i>	<i>19%</i>	
Other Rev. (Exp.)	(29)	(4)	
Net Income before Tax	192	191	1%
Net Income after Tax	170	172	-1%
<i>Net margin after tax</i>	<i>19%</i>	<i>17%</i>	
EPS (after tax)	0.22	0.23	

* Taiwan New Dollar per 1 US Dollar quarterly average:
2017Q1: 30.93, 2016Q1: 33.16



Balance Sheet- Consolidated

In NT\$ million	2017/03/31 (Reviewed)		2016/03/31 (Reviewed)	
Cash and Cash Equivalents	3,715	29%	2,560	21%
Accounts Receivable	635	5%	645	5%
Inventories	1,941	15%	2,167	17%
Long-Term Investments	364	3%	364	3%
Property, Plant & Equipment	5,155	40%	5,361	43%
Other Current/Non-Current Assets	1,043	8%	1,394	11%
Total Assets	12,853	100%	12,491	100%
Current Liabilities	1,692	13%	2,374	19%
Long-Term & Other Liabilities	803	6%	90	1%
Stockholders' Equities	10,358	81%	10,027	80%

Cash Flows- Consolidated

In NT\$ million	Q1, 2017 (Reviewed)	Q1, 2016 (Reviewed)
Cash and cash equivalents at beginning of period	3,707	2,336
Cash flows from operating activities	304	663
CAPEX	(203)	(264)
Short-term borrowings	(51)	(16)
Long-term borrowings	(41)	-
Others	(1)	(159)
Cash and cash equivalents at end of period	3,715	2,560

Free Cash flow

101


399



Historical Performance

Unit: millions of NT\$

■ Sales
■ Net Income



Recent Financials

In NT\$

Year	2013	2014	2015	2016
Total assets	11,484 M	11,372 M	12,222 M	12,783 M
Shareholders' equity	9,643 M	9,380 M	9,857 M	10,228 M
Sales	5,088 M	4,098 M	3,955 M	4,031 M
Net profit after tax	1,273 M	484 M	635 M	659 M
Earnings per share	1.88	0.69	0.87	0.87
Cash dividends	1.2	0.2	0.3	0.3
Stock dividends	0.4	0.4	0.4	0.4
Pay-out ratio	85%	87%	80%	80%

Note : All of the above figures represent consolidated information



Injectable Products Allied with Baxter


- ScinoPharm and Baxter Healthcare establish worldwide partnerships to co-develop and commercialize five niche generic injectable products at the initial stage
- ScinoPharm develops all APIs and injectable formulations. Baxter leads regulatory submissions in the US/EU and eventually market & sell the injectable products via its extensive presence in the hospital channel
- Both parties work on a cost-and-profit-sharing collaboration model
- Baxter has the right to add up to 15 additional injectable products for collaboration with ScinoPharm

Collaboration Framework

- Initial product portfolio including the generic injectables for breast cancer, lung cancer, multiple myeloma and antinauseant. Targeting US/EU markets first and expect to expand to other territories
- This exclusive partnership will utilize each other's strengths and expertise in order to achieve large scale of synergies in providing niche and affordable generic injectable products
- Commercial launch for the first 5 products upon FDA approval, with product launches beginning in 2020 and continuing thereafter
- Current branded sales of the initial five products included in this partnership total more than \$4 billion annually



Responsibilities by ScinoPharm and Baxter



Benefits of the Collaboration

- Aggressively expanding our “Double A” strategy for in-house developed/produced APIs and formulations. Providing an outlet for our injectable plant capacity
- A win-win solution and collaboration. ScinoPharm provides comprehensive APIs and formulation portfolio, while Baxter operates strong injectable product marketing channels throughout the US and worldwide
- Accelerate the momentum of our downstream integration strategy by establishing alliance with an world-renowned partner


2017 Product Launch Plan

Type	Product	Region	Indication	Brand Marketer	Regional Sales	WW Sales
Generic API	Desmopressin Acetate	USA	Polyuria	Ferring	US\$166M	US\$405M
Generic API	Tamsulosin HCl	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US\$333M	US\$1706M
New Drug API	Oncology Product	US	Non-Small Cell Lung Cancer	N/A	N/A	N/A
New Drug API	Oral Product	USA EU	Antibiotics	N/A	N/A	N/A
Generic Drug	Oncology Injectable	US	Myeloid Leukemia	MDS	US\$183M	US\$278M

Source: IMS Data (2015Q3-2016Q2)



Pipeline Outlook





Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT

